Skip to main content
. Author manuscript; available in PMC: 2019 Jun 26.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jun 26;130:50–57. doi: 10.1016/j.addr.2018.06.014

Figure 2.

Figure 2.

Nanoparticle PDAC access was improved by iRGD co-administration via a transcytosis mediated mechanism. (A) Schematic to show the working mechanism of iRGD peptide. (B) Ultrastructural viewing of a silicasome nanocarrier transport initiated by iRGD. KPC derived orthotopic tumor bearing mice were injected with 50 mg/kg Au-core containing silicasomes with co-administrated iRGD. Tumors were harvested at 24 hours and immediately fixed for TEM analysis. The electron micrograph shows silicasomes in (i) the lumen of a tumor blood vessel (red arrows), (ii) transport in the endothelial vesicles (pink arrow), and (iii) deposition in the tumor interstitium (blue arrows). High- magnification images of regions 1 through 3 are provided in the panels on the right. E, endothelial cell; P, pericyte. Scale bar: 2 μm (left panel); 50 nm (right panels). Picture adapted from Reference [49].